Hubei Province Key Laboratory of Oral and Maxillofacial Development and Regeneration, Wuhan, China.
Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Mol Genet Genomic Med. 2024 Aug;12(8):e2502. doi: 10.1002/mgg3.2502.
Hereditary hearing loss is an important component of congenital hearing loss. MARVELD2 (OMIM ID:610572), located in the DFNB49 locus, which encodes a tight junction protein tricellulin playing an important role in the sensory epithelial barrier of the inner ear, may contribute to nonsyndromic autosomal recessive hereditary hearing loss.
Two Han Chinese pedigrees with hearing loss underwent clinical and genetic analyses. Variants were detected by targeted next-generation sequencing and sequencing data were compared with the Human Genome Reference (GRCh 37/hg 19) to identify mutant genes and loci. Furthermore, online tools such as RDDC, SpliceAI, and REVEL were used to predict risks from different variants.
Both two probands failed neonatal hearing screening and were diagnosed with sensorineural hearing loss. A total of 3 mutations were detected in the two families, c.1331+1G>A, c.1325A>G, and c.782G>A. According to ACMG/AMP guidelines, they were judged to be pathogenic, uncertain significance, and uncertain significance, respectively.
These findings contribute to a better understanding of the relationship between different variants of MARVELD2 and hearing. This could further expand the spectrum of deafness gene mutations and contribute to deafness patient management and genetic counseling.
遗传性听力损失是先天性听力损失的重要组成部分。MARVELD2(OMIM ID:610572)位于 DFNB49 基因座,编码紧密连接蛋白 tricellulin,在内耳感觉上皮屏障中发挥重要作用,可能导致常染色体隐性遗传性非综合征型听力损失。
对 2 个有听力损失的汉族家系进行临床和遗传学分析。通过靶向下一代测序检测变异,将测序数据与人类基因组参考(GRCh 37/hg19)进行比较,以鉴定突变基因和基因座。此外,还使用在线工具,如 RDDC、SpliceAI 和 REVEL,从不同的变异体预测风险。
两个先证者均未通过新生儿听力筛查,被诊断为感音神经性听力损失。在这两个家庭中总共检测到 3 种突变,c.1331+1G>A、c.1325A>G 和 c.782G>A。根据 ACMG/AMP 指南,它们分别被判定为致病性、意义不明和意义不明。
这些发现有助于更好地理解 MARVELD2 不同变异体与听力之间的关系。这可能进一步扩大耳聋基因突变谱,有助于耳聋患者的管理和遗传咨询。